- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06012474
Effect Of Power Breath Device On Arterial Blood Gases And Diaphragmatic Excursion After Valve Surgery
August 23, 2023 updated by: Hend Mahdy Hassan Mohamed, Cairo University
The aim of this study is to evaluate the effect of power breath device on arterial blood gases, diaphragmatic excursion and the 6 min walk test after cardiac valve surgery.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
No more studies have been done on the effect of IMT by power breath on valvular surgery, So, this study will see the effect of power breath device on arterial blood gases, diaphragmatic excursion and six minute walk test after valve surgery to know enhanced recovery protocols in valvular surgery that accelerate the functional recovery, minimize the length of the hospital stay and decrease cost of treatment.
Study Type
Interventional
Enrollment (Actual)
50
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Dokki, Egypt
- Outpatient clinic faculty of physical therapy cairo university
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Female patients with valve surgery (valve replacement or repair with median sternotomy procedure).
- Age between 25 to 35 years old.
- BMI is between 18.5 to 24.5 kg/m2.
Exclusion Criteria:
The participants will be excluded if they meet one of the following criteria:
- Uncontrolled hypertension (systolic blood pressure>230 mm Hg and diastolic blood pressure>120 mm Hg)
- Patients with coronary artery disease or heart failure.
- Need for mechanical ventilation for >24 h or reintubation.
- Renal and hepatic disorders.
- Infected or unstable sternum.
- patient with pneumothorax after surgery.
- Metabolic disorders.
- Pregnant woman.
- Lactating mother.
- Smokers
- Stroke patient
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: inspiratory muscle training group
30 patients will receive inspiratory muscle training by Power breath device once daily for 7 days.
|
Power breath plus use a variable load calibrated spring.
It can be adjusted from the lowest load setting (17cmH2O) when training began and increased as the patient breathing muscles adapt and become stronger (maximum load setting 274cmH2O).
Use a comfortable chair, preferably straight-back so that the spine is straight at all times during the exercise.
patients will be instructed to exhale calmly, followed by a maximal forced inspiration to total lung capacity using a mouthpiece and a nasal clip as an aid to prevent air leaks and will ask to make 10 breaths for 3 sets once daily for 7 days with 2min rest between sets
The resistance will be increased incrementally, based on the rate of perceived exertion (RPE) scored by the patient on the modified Borg Scale.
If the RPE is less than 5, the resistance of the inspiratory trainer will be increased incrementally by 2cmH2O.
The resistance will not change if the level of perceived exertion is rated from 6 to 8, and the resistance will be decreased by 1 to 2 cmH2O if the level of perceived exertion is rated 9 or 10.
|
|
Active Comparator: diaphragmatic breathing exercise group
20 patients will receive program of diaphragmatic breathing exercise by incentive spirometer once daily for 7 days.
|
Training by using incentive spirometer:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Assessing the change in diaphragmatic excursion
Time Frame: within 24 hours after 1 week of intervention
|
By using Ultrasonography (Aloka prosound 4000, made in Japan) that will be used to assess diaphragmatic excursion.
Diaphragmatic excursion is measured 3 times :at baseline before surgical intervention, second day after surgery (before the training program) and after 7 days of training program for all patient in the two groups.
Diaphragmatic excursion was measured during deep breathing while the patient in semi-recumbent position on a comfortable bed using ultrasonography.
|
within 24 hours after 1 week of intervention
|
|
Assessing the change in Arterial Blood gases
Time Frame: within 24 hours after 1 week of intervention
|
Arterial blood gases are measured at baseline before surgical intervention, second day after surgery (before the training program) and after 7 days of training program for all patient in the two groups and can be obtained by direct arterial puncture most usually at the wrist (radial artery), femoral and brachial artery.
An arterial blood sample (2 to 3 ml) will be collected.
|
within 24 hours after 1 week of intervention
|
|
Assessing the change in capacity to perform daily activities
Time Frame: within 24 hours after 1 week of intervention
|
by using the The 6-min walk test (6MWT) is a submaximal functional test indicative of the capacity to perform daily activities, patients will be asked to walk along a 30-m, flat and straight hospital corridor.
Encouragement will be offered every minute, so that subjects will walk as far as possible.
Symptom-limited interruptions (dyspnea, skeletal muscle pain, angina, dizziness) will allowed, though patients will be invited to resume walking as soon as possible.
Most tests will be supervised by a physical therapist.
Distance will be recorded in meters.
Subjective dyspnea will quantified according to Borg Scale, ranging from 0 (no dyspnea) to 10 (severe dyspnea).
|
within 24 hours after 1 week of intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Hend Mahdy, Cairo University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2022
Primary Completion (Actual)
May 15, 2022
Study Completion (Actual)
October 15, 2022
Study Registration Dates
First Submitted
August 21, 2023
First Submitted That Met QC Criteria
August 23, 2023
First Posted (Actual)
August 25, 2023
Study Record Updates
Last Update Posted (Actual)
August 25, 2023
Last Update Submitted That Met QC Criteria
August 23, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 012/004209
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Valve Diseases
-
National University of Ireland, Galway, IrelandNot yet recruitingSurgical Valve Replacement | AORTIC VALVE DISEASES | Valve Disease, Aortic | Valve-in-valve ProceduresIreland
-
IRCCS Policlinico S. DonatoRecruitingMitral Valve Prolapse | Myxomatous Mitral Valve DegenerationItaly
-
Michael MorontRecruitingValve Disease, Heart | Valve Replacement | Valve Heart Stenosis | Valve Regurgitation, MitralUnited States
-
Centro Cardiologico MonzinoAzienda Ospedaliero-Universitaria di Parma; Policlinico SS Annunziata di ChietiActive, not recruitingMitral Regurgitation | Mitral Valve ProlapseItaly
-
Meril Life Sciences Pvt. Ltd.Not yet recruitingAortic Valve Disease, Mitral Valve Disease, Prosthetic Heart Valve Dysfunction | Valvular Heart Disease Requiring Surgical Aortic or Mitral Valve Replacement
-
TRiCaresRecruitingCardiovascular Diseases | Heart Valve Disease | Tricuspid Valve RegurgitationBelgium, Germany
-
University of SalernoActive, not recruitingMitral Valve Failure | AORTIC VALVE DISEASESItaly
-
National Heart, Lung, and Blood Institute (NHLBI)WithdrawnHeart Failure | Aortic Valve Stenosis | Mitral Valve Regurgitation | Heart Valve Disease | Tricuspid Valve RegurgitationUnited States
-
Boston Children's HospitalRecruitingValve Disease, Heart | Valve Heart Disease | Valve Disease, AorticUnited States
-
Medical College of WisconsinChildren's Hospital and Health System Foundation, WisconsinCompletedMitral Valve Regurgitation | Tricuspid Valve Regurgitation, Non-rheumaticUnited States
Clinical Trials on Power breath plus
-
Old Dominion UniversityCompletedAnxiety | Visceral Pain | Gastrointestinal System--AbnormalitiesUnited States
-
University of Maryland, BaltimoreNational Institute of Nursing Research (NINR)CompletedOsteoporosis | Health Behaviors
-
Qassim UniversityCairo University; Prince Sattam Bin Abdulaziz UniversityCompletedHernias, Diaphragmatic, CongenitalSaudi Arabia
-
Second Affiliated Hospital, School of Medicine,...RecruitingHelicobacter Pylori EradicationChina
-
University of OklahomaU.S. Department of EducationCompletedCerebral Palsy | Child, PreschoolUnited States
-
De Sire AlessandroRecruiting
-
Youngstown State UniversityCompleted
-
Nova Southeastern UniversityJohn H. Stroger HospitalCompletedRisk Reduction | Unsafe SexUnited States
-
Sana'a UniversityCompletedMalocclusion | Orthodontic TreatmentYemen